Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) Given Average Rating of “Hold” by Brokerages

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) has been assigned an average recommendation of “Hold” from the five analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $16.00.

A number of research firms recently weighed in on NTHI. Maxim Group began coverage on shares of Neonc Technologies in a research report on Monday, May 18th. They set a “buy” rating and a $20.00 price target on the stock. Alliance Global Partners started coverage on Neonc Technologies in a report on Tuesday, May 19th. They set a “buy” rating and a $13.00 target price on the stock. BTIG Research restated a “buy” rating and issued a $15.00 price target on shares of Neonc Technologies in a research report on Tuesday, September 8th. Weiss Ratings raised Neonc Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 31st. Finally, Wall Street Zen downgraded Neonc Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th.

Insider Buying and Selling at Neonc Technologies

In other news, CEO Amir F. Heshmatpour acquired 12,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was purchased at an average price of $3.79 per share, with a total value of $45,480.00. Following the completion of the acquisition, the chief executive officer owned 3,084,000 shares of the company’s stock, valued at $11,688,360. This trade represents a 0.39% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Thomas C. Chen acquired 12,757 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were purchased at an average price of $5.49 per share, with a total value of $70,035.93. Following the completion of the transaction, the chief executive officer owned 13,705 shares of the company’s stock, valued at $75,240.45. The trade was a 1,345.68% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have bought 36,757 shares of company stock worth $178,486.

Institutional Trading of Neonc Technologies

Several hedge funds have recently made changes to their positions in the company. Royal Bank of Canada acquired a new stake in shares of Neonc Technologies during the 1st quarter worth approximately $247,000. Bank of America Corp DE purchased a new position in Neonc Technologies in the second quarter worth approximately $801,000. Vanguard Group Inc. acquired a new stake in Neonc Technologies during the third quarter worth $1,279,000. HighPoint Advisor Group LLC increased its stake in Neonc Technologies by 20.5% during the fourth quarter. HighPoint Advisor Group LLC now owns 1,144,640 shares of the company’s stock worth $9,466,000 after acquiring an additional 194,408 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in Neonc Technologies during the fourth quarter worth $124,000.

Neonc Technologies Price Performance

NASDAQ NTHI opened at $3.68 on Wednesday. The business has a fifty day moving average price of $4.07 and a 200 day moving average price of $5.36. Neonc Technologies has a one year low of $3.01 and a one year high of $12.99.

Neonc Technologies (NASDAQ:NTHI) last announced its earnings results on Monday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.46).

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.